Financial Performance - For the full year 2025, the company reported revenue of $2.939 billion, representing a growth of 16.7% year-over-year, and non-GAAP earnings per share of $3.98, growing 30.8% [5][24] - In Q4 2025, revenue totaled $826.4 million, growing 25.7% compared to Q4 2024, with non-GAAP EPS at $1.28, a growth of 52.1% [6][25] - The base business revenue for Q4 was $726.7 million, growing 10.6% year-over-year, with a consolidated Adjusted EBITDA margin of 33.9% [6][25] Business Line Performance - The U.S. spine business grew 10% in Q4 compared to the prior year quarter, continuing a trend of above-market growth [7][28] - Enabling Technologies revenue reached $55.6 million in Q4, growing 18.5% year-over-year, driven by increased sales of EGPS systems [11][27] - The trauma business delivered approximately 27% growth in Q4, supported by the uptake of the legacy trauma line and new product launches [15][16] Market Performance - U.S. revenue in Q4 was $665.3 million, growing 27.5% year-over-year, while international revenue was $161.1 million, growing 19% [27][28] - The international spine business faced challenges earlier in the year but showed incremental improvement, culminating in a record sales quarter in Q4 2025 [29][28] - Growth in international markets was led by enabling technologies and the spine business, particularly in the UK, Australia, Germany, Brazil, Mexico, and Poland [28] Company Strategy and Industry Competition - The company aims to penetrate and launch new programs while fostering utilization and service excellence across its install base, with a focus on innovation in product development [15][18] - The integration of Nevro is expected to enhance the company's portfolio, allowing entry into adjacent markets while driving differentiation in legacy businesses [18][17] - The company remains competitive in the evolving market landscape, emphasizing the unique capabilities of its ExcelsiusGPS platform [12][14] Management Commentary on Operating Environment and Future Outlook - Management expressed confidence in the sustainability of U.S. spine growth, citing product launches and an expanded sales force as key drivers [70] - The company anticipates continued margin expansion, with a target of achieving a gross profit margin in the range of 69%-70% for 2026 [32][43] - Management acknowledged the challenges faced in international markets but remains optimistic about returning to double-digit growth rates as the year progresses [81][80] Other Important Information - The company repurchased approximately 4.3 million shares during 2025, with a new share repurchase program of $500 million announced [38][39] - Full-year 2025 SG&A expenses were $1.178 billion, or 40% of sales, with expectations for 2026 to be in the range of 38%-39% [36][43] - The company achieved $200 million in synergies from the NuVasive acquisition, exceeding initial targets [41][42] Q&A Session Summary Question: Can you bridge the growth expectations for the base business from 2025 to 2026? - Management noted that 2025 was a tale of two halves, with significant growth in the latter half driven by product launches and sales force expansion [49][50] Question: How did the company perform in terms of market share and the strength of the spine market? - Management believes the U.S. spine business is growing above market, with evidence from consistent growth rates [56][57] Question: What contributed to the recovery in enabling technology performance? - Management indicated that the fourth quarter saw a closure of delayed pipeline deals, contributing to the improved performance [62][63] Question: How sustainable is the U.S. spine growth, especially with new competition? - Management expressed confidence in the durability of U.S. spine growth, emphasizing ongoing product launches and competitive strategies [70][71] Question: What are the challenges and growth prospects for the international business? - Management highlighted the potential for 12%-15% growth in international markets, focusing on deeper penetration rather than expansion into new countries [81][80]

Financial Performance - For the full year 2025, Globus Medical reported revenue of $2.939 billion, representing a growth of 16.7% year-over-year, and non-GAAP earnings per share of $3.98, up 30.8% [6][24] - In Q4 2025, revenue reached $826.4 million, growing 25.7% compared to Q4 2024, with non-GAAP EPS at $1.28, a 52.1% increase [7][25] - The adjusted gross margin for Q4 was 69.2%, compared to 67.1% in the prior year quarter, driven by favorable sales mix and synergy execution [30][31] Business Line Performance - The U.S. spine business grew 10% in Q4 2025 compared to the prior year quarter, continuing a trend of above-market growth [8][28] - Enabling Technologies revenue was $55.6 million in Q4, growing 18.5% year-over-year, driven by increased sales of EGPS systems [12][27] - The trauma business delivered approximately 27% growth in Q4, supported by the legacy trauma line and new product launches [16][17] Market Performance - U.S. revenue in Q4 2025 was $665.3 million, growing 27.5% year-over-year, while international revenue was $161.1 million, growing 19% [27][28] - The international spine business faced challenges earlier in the year but showed improvement, culminating in record sales in Q4 2025 [29][83] Company Strategy and Industry Competition - The company aims to expand its core spine business while growing other segments, positioning itself as a procedure-enabling medtech platform integrating imaging, navigation, robotics, and implants [19][20] - The competitive landscape is evolving, with new robotic navigation systems entering the market, but the company believes its ExcelsiusGPS system remains a strong option for customers [13][73] Management Commentary on Operating Environment and Future Outlook - Management expressed confidence in sustained growth momentum, particularly in the U.S. spine business, and anticipates continued above-market growth in 2026 [9][71] - The company expects to achieve a full-year adjusted gross margin of 69%-70% in 2026, reflecting ongoing improvements in manufacturing initiatives [32][43] Other Important Information - The company repurchased approximately 4.3 million shares for $300.5 million during 2025, with a new share repurchase program of $500 million announced [39] - Full-year 2025 SG&A expenses were $1.178 billion, or 40% of sales, with expectations for 2026 to be in the range of 38%-39% [36] Q&A Session Summary Question: Can you bridge the growth expectations for the base business into 2026? - Management noted that 2025 was a tale of two halves, with significant growth in the latter half driven by product launches and sales force expansion [49][50] Question: How do you view market share and the strength of the spine market? - Management believes the U.S. spine business is growing above market and views the overall spine market as relatively healthy [58] Question: What changed in the enabling technology environment? - Management indicated that enabling technology performance was lumpy throughout the year, with a strong Q4 driven by closing delayed pipeline deals [62][63] Question: How sustainable is the U.S. spine growth? - Management sees the growth as durable, supported by ongoing product launches and competitive rep conversions [71][72] Question: What are the headwinds in the international market? - Management identified challenges in the APAC region, particularly Japan, but believes there are ample opportunities for growth in existing markets [82][83]

Core Insights - Revolve Group reported revenue of $296.71 million for the quarter ended March 2025, reflecting a 9.7% increase year-over-year and a surprise of +0.24% over the Zacks Consensus Estimate of $296 million [1] - The company's EPS was $0.16, up from $0.15 in the same quarter last year, with an EPS surprise of +23.08% compared to the consensus estimate of $0.13 [1] Financial Performance Metrics - Total orders placed were 2.31 million, matching the four-analyst average estimate [4] - Average order value was $295, lower than the estimated $305.48 by four analysts [4] - Active customers reached 2.7 million, slightly above the three-analyst average estimate of 2.69 million [4] - Geographic Net Sales for the Rest of the World were $57.47 million, below the estimated $59.35 million but showing an 11.7% increase year-over-year [4] - Geographic Net Sales in the United States were $239.24 million, exceeding the estimate of $236.04 million and representing a 9.2% year-over-year increase [4] - Net Sales for FWRD were $42.31 million, below the five-analyst average estimate of $45.23 million, with a year-over-year change of +3.2% [4] - Net Sales for REVOLVE were $254.40 million, surpassing the $250.39 million average estimate and showing a +10.8% change year-over-year [4] - Gross profit for FWRD was $15.50 million, slightly below the three-analyst average estimate of $15.99 million [4] - Gross profit for REVOLVE was $138.79 million, slightly above the three-analyst average estimate of $138.58 million [4] Stock Performance - Shares of Revolve Group have returned -2.8% over the past month, contrasting with the Zacks S&P 500 composite's +11.5% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Financial Data and Key Metrics Changes - The company reported net sales of $297 million, a year-over-year increase of 10% [32] - Operating income increased by 57% year-over-year, with adjusted EBITDA rising by 45% [8][36] - Cash and cash equivalents exceeded $300 million for the first time, increasing by $44 million or 17% in just three months [40][31] - The gross margin was 52%, a decrease of 30 basis points year-over-year, primarily due to a lower mix of net sales at full price and deeper markdowns [34] Business Line Data and Key Metrics Changes - REVOLVE segment net sales increased by 11% year-over-year, while FORWARD segment net sales increased by 3% [33] - The product return rate decreased by nearly three points year-over-year, contributing to operational efficiencies [10] - The mix of owned brand net sales as a percentage of REVOLVE segment net sales increased year-over-year for the first time in two and a half years [25] Market Data and Key Metrics Changes - Domestic net sales increased by 9% year-over-year, while international net sales increased by 12% [33] - Active customers increased by 6% year-over-year, reaching 2.7 million [33] - The company noted a shift in consumer behavior towards more accessible price points, impacting average order value [34][60] Company Strategy and Development Direction - The company is focused on long-term investments in AI technology, international expansion, and building owned brands [8][12] - The REVOLVE Festival was highlighted as a successful brand-building event, generating significant marketing impact and consumer engagement [21][24] - The company is exploring physical retail opportunities, with plans to open a permanent store in Los Angeles [26][28] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges posed by geopolitical and macroeconomic uncertainties, particularly regarding tariffs [11] - The leadership team expressed confidence in navigating through current uncertainties, citing a strong track record during previous turbulent periods [12][46] - The company is moderating internal revenue growth expectations for the full year due to declining consumer confidence [48][76] Other Important Information - The company generated $45 million in operating cash flow in the first quarter, significantly strengthening its balance sheet [10][38] - The company has no debt and has increased its cash and cash equivalents balance fourfold over the last five years [40] - The company is actively working on tariff mitigation strategies, including diversifying manufacturing sources and optimizing logistics [44][45] Q&A Session Summary Question: Can you clarify the gross margin guidance related to tariffs? - Management confirmed that the low end of the gross margin guidance assumes elevated tariff rates with their best estimate of mitigation efforts [56][57] Question: How quickly can the company pivot to third-party sourced inventory? - Management indicated that while they can flex inventory sourcing, the focus remains on owned brand expansion, with diversification efforts expected to take longer [58][59] Question: Is the company seeing any impact on customer traffic and conversion trends due to tariffs? - Management noted a shift to more accessible price points is impacting average order value, reflecting consumer sentiment [60][61] Question: Are there plans to increase promotional activities to stimulate demand? - Management stated that while they are seeing a shift to more accessible price points, they are not changing their markdown strategy in response to market conditions [70][71] Question: What feedback is the company receiving from third-party brands regarding price increases? - Management reported that they are seeing some price increases from third-party brands but have not yet received significant customer pushback [79][80]